Quantum BioPharma Ltd.

https://www.quantumbiopharma.com

Quantum BioPharma Ltd. is a biopharmaceutical company headquartered in Toronto, Ontario, Canada, dedicated to developing innovative assets and biotech solutions. The company's mission is to improve the quality of life for patients by developing novel solutions for brain and inflammatory disorders. It focuses on challenging neurodegenerative, metabolic, and alcohol misuse disorders.

The company's primary product candidate is Lucid-MS (formerly Lucid-21-302), a patented neuroprotective compound in development for Multiple Sclerosis (MS). Lucid-MS has demonstrated in preclinical models the ability to prevent and reverse myelin degradation, the underlying mechanism of MS, and has completed Phase 1 clinical trials. Quantum BioPharma also invented unbuzzd™, a dietary supplement designed to accelerate alcohol metabolism and reduce hangover symptoms, which it has licensed to Unbuzzd Wellness Inc., retaining ownership and royalty interests. Additionally, the company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., including real estate-secured loans and a digital asset portfolio.

In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the FDA for a Phase 2 clinical trial of Lucid-MS. Recent peer-reviewed clinical trial results for unbuzzd™ confirmed its efficacy in accelerating alcohol metabolism and reducing intoxication symptoms. Zeeshan Saeed serves as the company's CEO, appointed in June 2023. The company operates in multi-billion dollar markets for neurodegenerative diseases and alcohol misuse disorders, with a market capitalization of approximately $21.0 million as of April 2026.

Latest updates

Buzbuzian Joins Unbuzzd Wellness as CEO Amidst Functional Beverage Growth

Event summary

  • Richard Buzbuzian has been appointed CEO of Unbuzzd Wellness Inc., formerly Celly Nutrition Corp.
  • Unbuzzd Wellness is commercializing 'unbuzzd,' a beverage clinically validated to accelerate alcohol metabolism and reduce hangover symptoms.
  • The functional beverage market is projected to reach $198 billion in 2026, with a 10.79% CAGR.
  • Unbuzzd Wellness plans to expand into South Florida and Texas, and pursue a stock exchange listing.
  • Quantum BioPharma retains a 19.84% ownership stake in Unbuzzd Wellness and is entitled to royalties up to $250 million.

The big picture

Unbuzzd Wellness is capitalizing on the rapidly expanding functional beverage market, driven by consumer demand for health-conscious options. The appointment of a CEO with capital markets experience signals an intent to scale rapidly and pursue public listing, but the company's success depends on navigating regulatory hurdles and maintaining a competitive edge in a crowded space. Quantum BioPharma's continued involvement through royalties and ownership provides a financial incentive for Unbuzzd Wellness's growth, but also introduces a layer of complexity in governance and strategic alignment.

What we're watching

Execution Risk
The success of Unbuzzd Wellness hinges on Buzbuzian's ability to execute the nationwide rollout and secure retail partnerships, particularly in competitive markets like South Florida and Texas.
Regulatory Headwinds
Increased scrutiny of functional beverages and their health claims could impact Unbuzzd Wellness's marketing and distribution strategies, requiring careful navigation of regulatory landscapes.
Governance Dynamics
The transition from Duffy’s leadership to Buzbuzian’s, and the ongoing royalty structure with Quantum BioPharma, will shape Unbuzzd Wellness’s financial performance and strategic direction.

Quantum BioPharma Lawsuit Against CIBC, RBC Advances

Event summary

  • Quantum BioPharma’s lawsuit against CIBC World Markets and RBC Dominion Securities alleging market manipulation has survived a motion to dismiss.
  • The lawsuit claims the defendants used “spoofing” techniques to manipulate Quantum BioPharma’s share price between January 1, 2020, and August 15, 2024.
  • The alleged manipulation violates Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934.
  • Quantum BioPharma alleges damages totaling USD $700 million.

The big picture

This case highlights the increasing regulatory focus on market manipulation, particularly concerning smaller biopharmaceutical companies vulnerable to speculative trading. The $700 million claim represents a substantial potential liability for CIBC and RBC, and the denial of the motion to dismiss suggests the court finds merit in Quantum BioPharma’s allegations. The outcome could set a precedent for similar claims against investment banks and impact investor behavior in the biotech sector.

What we're watching

Legal Exposure
The outcome of the lawsuit will significantly impact Quantum BioPharma’s financial outlook and investor confidence, potentially requiring substantial legal expenses and settlements if found liable.
Share Volatility
Continued litigation will likely contribute to ongoing share price volatility as investors assess the potential financial and reputational risks associated with the allegations.
Advisor Oversight
The case may prompt increased regulatory scrutiny of investment banks and their compliance procedures regarding market manipulation and trading practices.

Quantum BioPharma Advances MS Candidate with FDA IND Submission

Event summary

  • Quantum BioPharma submitted an Investigational New Drug (IND) application to the FDA for Lucid-MS, its multiple sclerosis treatment candidate, on April 1, 2026.
  • The IND submission supports a planned Phase 2 clinical trial evaluating Lucid-MS, which targets demyelination—a novel approach compared to existing MS therapies.
  • Phase 1 trials indicated Lucid-MS was safe and well-tolerated.
  • Quantum BioPharma retains a 19.84% stake in Unbuzzd Wellness Inc. (UWI) and receives a 7% royalty on sales until $250 million is reached, then 3% perpetually.

The big picture

The MS therapeutic market, projected to exceed $38 billion by 2030, is ripe for innovation, particularly therapies addressing the underlying neurodegenerative mechanisms. Quantum BioPharma’s differentiated approach targeting demyelination positions it to potentially capture market share, but success hinges on FDA approval and demonstrating clinical efficacy in Phase 2 trials. The company's unusual diversification into consumer health products like Unbuzzd adds complexity to its financial model and long-term value proposition.

What we're watching

Regulatory Risk
The FDA’s response to the IND submission, expected in Q2 2026, will dictate the timeline for Phase 2 trial initiation and represents a key near-term catalyst.
Clinical Efficacy
Phase 2 trial data, projected for Q4 2026, will be critical in determining whether Lucid-MS’s novel demyelination-targeting mechanism translates to meaningful clinical benefit for MS patients.
Financial Sustainability
The interplay between Lucid-MS development costs and revenue from Unbuzzd Wellness will determine if Quantum BioPharma can maintain its diversified business platform without shareholder dilution.

Quantum BioPharma Outsources Phase 2 Trial for Lucid-MS

Event summary

  • Quantum BioPharma has signed a binding Letter of Intent (LOI) with Allucent to conduct a Phase 2 clinical trial for its Lucid-MS treatment.
  • The trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in patients with multiple sclerosis, expected to begin in Q2 2026.
  • Allucent will provide comprehensive clinical trial services, including regulatory submissions, site management, patient recruitment, and data management.
  • Lucid-MS targets demyelination, a differentiated approach compared to existing MS treatments primarily focused on immune modulation.
  • Quantum BioPharma retains a significant tax loss carry forward of approximately C$130 million.

The big picture

Quantum BioPharma's partnership with Allucent represents a critical step in validating its differentiated approach to treating multiple sclerosis, a market projected to exceed $38 billion by 2030. Outsourcing the Phase 2 trial to a specialized CRO like Allucent reflects a common strategy among smaller biopharma companies lacking in-house clinical development expertise. The trial's outcome will be pivotal in determining whether Lucid-MS can carve out a niche in a crowded market dominated by immune-modulating therapies.

What we're watching

Execution Risk
The success of Lucid-MS hinges on the efficient and rigorous execution of the Phase 2 trial by Allucent, given the complexity of CNS trials and the need for robust data integrity.
Clinical Efficacy
The trial results will determine whether Lucid-MS’s novel mechanism of targeting demyelination translates into meaningful clinical improvements for MS patients, a key factor in its commercial viability.
Regulatory Pathway
The speed and smoothness of regulatory approvals for the Phase 2 trial and subsequent phases will be crucial for Quantum BioPharma to capitalize on the substantial market opportunity in MS.

Quantum BioPharma Secures Funding, Advances MS Drug Candidate

Event summary

  • Quantum BioPharma reported $11.3 million USD in cash and digital assets as of December 31, 2025, projecting basic operations sustainability through January 2028.
  • The company has secured financing from convertible debt, institutional loans, and loan portfolio monetization, improving capital market access.
  • Phase 1 toxicology studies for Lucid-MS (Multiple Sclerosis drug candidate) showed no significant side effects.
  • Unbuzzd Wellness, a licensee, is pursuing a Regulation D 506(c) offering to raise up to $5.0 million USD, with Quantum retaining a stake.
  • Terry Lynch resigned from the board of directors, citing time constraints.

The big picture

Quantum BioPharma’s ability to maintain a ‘no going concern’ status, coupled with improved capital market access, suggests a stabilization of its financial position after previous concerns. The advancement of Lucid-MS, particularly the oral formulation, represents a potential breakthrough in MS treatment, a market with significant unmet need. However, the company’s reliance on Unbuzzd Wellness for near-term monetization introduces a layer of complexity and dependence on a separate entity’s success.

What we're watching

Financial Stability
The success of the $5.0 million USD offering will be critical for Unbuzzd Wellness and will impact Quantum’s retained stake and potential revenue streams.
Clinical Progress
The speed of Phase 2 clinical trial enrollment and data readouts for Lucid-MS will determine the viability of Quantum’s core pipeline and investor confidence.
Litigation Risk
The outcome of the lawsuit against CIBC and RBC regarding alleged stock market manipulation could significantly impact Quantum’s financial standing and reputation.

Quantum BioPharma Taps MS Expert Ahead of Phase 2 Trial

Event summary

  • Quantum BioPharma appointed Dr. Salvatore Napoli, MD, as Principal Investigator for the planned Phase 2 clinical trial of Lucid-MS.
  • Dr. Napoli is President and Medical Director of the Neurology Center of New England and the MS Center of New England.
  • Quantum BioPharma plans to submit an Investigational New Drug (IND) application to the FDA in the coming weeks.
  • Lucid-MS is a patented New Chemical Entity (NCE) targeting demyelination in Multiple Sclerosis.

The big picture

The appointment of a recognized MS expert like Dr. Napoli signals Quantum BioPharma's commitment to advancing Lucid-MS, a novel therapy targeting demyelination. The MS market remains a significant area of unmet need, with existing treatments often failing to adequately address disease progression. However, the Phase 2 trial represents a high-risk, high-reward endeavor, and the company's future hinges on demonstrating Lucid-MS's efficacy and safety.

What we're watching

Regulatory Risk
The success of this initiative hinges on FDA clearance of the IND application, which could be delayed or denied based on preclinical data or trial design.
Clinical Efficacy
The Phase 2 trial's results will be critical in determining Lucid-MS's true efficacy in treating MS, and a failure to demonstrate meaningful benefit could significantly impact Quantum BioPharma's valuation.
Commercialization
Given the crowded MS treatment landscape, Quantum BioPharma will need to demonstrate a clear competitive advantage for Lucid-MS to achieve commercial success, particularly regarding its non-immunomodulatory mechanism.

Quantum BioPharma Validates 'Unbuzzd' Efficacy in Peer-Reviewed Trial

Event summary

  • Quantum BioPharma published a peer-reviewed clinical trial (NCT06505239) in the World Journal of Pharmaceutical and Medical Research, validating the efficacy of its 'unbuzzd' dietary supplement.
  • The trial demonstrated that 'unbuzzd' significantly accelerated alcohol metabolism (average 40% faster within 30 minutes) and reduced symptoms of intoxication compared to a placebo.
  • Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc. and receives royalties of 7% on sales until $250 million is reached.
  • The company retains a $130 million tax loss carry forward that could offset future profits.

The big picture

Quantum BioPharma's validation of 'unbuzzd' through a peer-reviewed trial challenges the long-held belief that alcohol metabolism is largely fixed, potentially disrupting the alcohol consumption landscape. The licensing agreement with Unbuzzd Wellness Inc. represents a strategic move to leverage a rapidly growing market for hangover remedies and responsible alcohol consumption aids. The company's retained ownership and royalty structure provides a revenue stream tied to the success of 'unbuzzd' while allowing Unbuzzd Wellness Inc. to focus on distribution and marketing.

What we're watching

Market Adoption
The speed at which consumer adoption of 'unbuzzd' occurs will depend on marketing efforts and consumer perception of its efficacy and safety, particularly given the claims of accelerating alcohol metabolism.
Regulatory Scrutiny
Increased regulatory scrutiny of dietary supplements making health claims related to alcohol metabolism is possible, potentially impacting 'unbuzzd'’s market access and marketing messaging.
Royalty Impact
The pace of 'unbuzzd' sales will determine how quickly Quantum BioPharma reaches the $250 million royalty threshold, impacting future revenue streams.

Quantum BioPharma Secures $3.75M, Settles Debt with Insider Participation

Event summary

  • Quantum BioPharma closed an initial tranche of a private placement offering, raising $3.75 million via the issuance of 3,750 Debenture Units.
  • A director of the company, the 'Director Subscriber,' participated, investing $300,000 in Debenture Units, constituting a related-party transaction.
  • The company settled approximately $1.12 million in debt by issuing 370,457 Class B subordinate voting shares to arm’s length creditors and insiders.
  • The company is relying on exemptions under MI 61-101 for both the private placement and the debt settlement, avoiding formal valuation and shareholder approval requirements.

The big picture

Quantum BioPharma's capital raise provides short-term funding but highlights the ongoing need for external financing in the biopharmaceutical sector, particularly for companies with assets in early development stages. The related-party transactions raise governance questions common in smaller, publicly-traded biotech firms. The debt settlement, while reducing liabilities, dilutes existing shareholders and introduces new insiders with a vested interest in the company's performance.

What we're watching

Capital Adequacy
The company's ability to complete the remaining tranches of the offering will be crucial for funding ongoing development, and any shortfall could signal broader investor concerns.
Governance Dynamics
The reliance on exemptions from MI 61-101, coupled with the director's substantial participation, warrants scrutiny regarding potential conflicts of interest and shareholder protections.
Celly Nutrition
The royalty agreement with Celly Nutrition, while potentially lucrative, introduces a dependency on the success of a separate entity and its OTC product, UNBUZZD.

Quantum BioPharma Revises Debenture Terms Amid Share Price Decline

Event summary

  • Quantum BioPharma has revised the terms of its Debenture Units following a decrease in the price of its Class B subordinate voting shares.
  • The conversion price per share has been reduced to $3.00, up from a previous, undisclosed price.
  • The number of warrants included in each Debenture Unit has increased to 333.33.
  • The exercise price per warrant share has been lowered to $3.75.
  • The Debt Settlement will also be completed at the revised, lower conversion price.

The big picture

Quantum BioPharma's adjustment of debenture terms highlights the challenges faced by smaller biopharma companies in securing funding and maintaining investor interest. The move suggests a need to incentivize investment, likely reflecting broader market concerns about the company's valuation and growth prospects. This restructuring, while common, can signal underlying financial stress and may impact the company's ability to pursue its development pipeline.

What we're watching

Shareholder Confidence
The revision of debenture terms signals a lack of investor confidence, potentially impacting future capital raising efforts and overall valuation.
Financial Health
The company's ability to manage its debt obligations and maintain a positive cash flow will be critical, especially given the reduced conversion price and increased warrant allocation.
Celly Nutrition Impact
The royalty agreement with Celly Nutrition, while currently providing income, could become a point of contention if the company seeks to restructure its finances further.

Quantum BioPharma Secures Convertible Debenture Offering Amidst Debt Settlement

Event summary

  • Quantum BioPharma intends to complete a non-brokered private placement of up to 4,000 convertible debenture units, priced at $1,000 per unit.
  • Each unit comprises a $1,000 debenture and 250 warrants exercisable for Class B subordinate voting shares at $5.00 per share.
  • The company will also settle debts owed to creditors and insiders through the issuance of shares at a deemed price of $4.00 per share.
  • Proceeds from the offering will be used for ongoing business development and general working capital.

The big picture

Quantum BioPharma’s reliance on convertible debentures and debt settlements suggests ongoing financial constraints and a need to raise capital. The structure of the offering, with warrants and a relatively high conversion price, indicates an attempt to incentivize investment while minimizing immediate dilution. The related-party transaction, while seemingly compliant with regulatory exemptions, raises governance concerns and could be a point of investor skepticism.

What we're watching

Financial Health
The success of this offering and the ability to service the 1.25% monthly interest payments will be critical to Quantum BioPharma’s short-term liquidity and solvency.
Share Dilution
The conversion of debentures and the issuance of shares for debt settlement will significantly dilute existing shareholders, potentially impacting the stock price and future earnings per share.
Regulatory Scrutiny
The reliance on exemptions from MI 61-101 regarding the related party transaction could draw scrutiny from regulators and investors, particularly given the expedited timeline.

Quantum BioPharma Completes Toxicity Studies for MS Candidate, Paving Way for Phase 2

Event summary

  • Quantum BioPharma has completed 180-day repeated dose oral toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS).
  • The completion of these studies is a prerequisite for filing an Investigational New Drug (IND) application with the US FDA.
  • The data will inform the design of a Phase 2 clinical trial for Lucid-MS in patients with multiple sclerosis (MS).
  • Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc. as of September 30, 2025.

The big picture

The successful completion of these toxicity studies represents a significant milestone for Quantum BioPharma, positioning Lucid-MS as a potential first-in-class treatment for multiple sclerosis, a market with substantial unmet need. The company's strategy of developing treatments for neurodegenerative and metabolic disorders, coupled with its spin-off of Unbuzzd Wellness, highlights a diversified approach to revenue generation. However, the company's reliance on litigation proceeds and strategic investments introduces financial risk that investors should monitor closely.

What we're watching

Regulatory Approval
The FDA’s review of the IND application will be critical; delays or requests for additional data could significantly impact the timeline for Phase 2 trials.
Clinical Trial Design
The design of the Phase 2 trial, particularly the endpoints selected, will heavily influence the likelihood of demonstrating efficacy and advancing Lucid-MS.
Financial Resources
Quantum BioPharma’s ability to secure sufficient funding to support the Phase 2 trial and ongoing operations will be a key determinant of Lucid-MS’s progression.

Quantum BioPharma Faces Class Action Over Alleged Bank Manipulation

Event summary

  • Grant & Eisenhofer, a prominent law firm, filed a class action lawsuit against CIBC and RBC alleging stock market manipulation of Quantum BioPharma shares.
  • The lawsuit claims manipulation occurred between January 6, 2021, and October 15, 2025, impacting shareholders who sold their securities.
  • Quantum BioPharma intends to seek appointment as a lead plaintiff to assist in protecting its shareholders.
  • The company has renewed legal services with LWM for a one-month period, starting December 22, 2025.
  • Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc. and receives royalties until $250 million is paid.

The big picture

The lawsuit highlights the increasing scrutiny of financial institutions' trading practices and the potential for legal action when market manipulation is suspected. While Quantum BioPharma's involvement is as a plaintiff, the allegations against CIBC and RBC, two of Canada's largest banks, carry significant reputational and financial risk. This case could set a precedent for future litigation related to alleged stock market manipulation, particularly concerning smaller biotech companies.

What we're watching

Litigation Risk
The outcome of the class action lawsuit will significantly impact Quantum BioPharma's financial standing and reputation, potentially leading to substantial legal fees and settlements.
Regulatory Response
Canadian regulators may investigate the alleged market manipulation, which could result in further penalties and increased scrutiny of CIBC and RBC's trading practices.
Shareholder Confidence
The lawsuit’s progression will likely influence investor sentiment and trading volume for Quantum BioPharma, potentially impacting its ability to secure future funding.

Quantum BioPharma Faces Class Action Over Alleged Bank Manipulation

Event summary

  • Shareholder Paul Durkacz filed a class action lawsuit against CIBC and RBC alleging stock market manipulation of Quantum BioPharma shares.
  • The lawsuit claims manipulation occurred between January 6, 2021, and October 15, 2025, impacting shareholders who sold securities.
  • Quantum BioPharma intends to seek appointment as a lead plaintiff in the class action.
  • The company has renewed legal services with LWM for one month, starting December 22, 2025.

The big picture

The lawsuit highlights the increasing regulatory focus on potential market manipulation, particularly concerning smaller biotech firms. The involvement of major Canadian banks adds significant weight to the allegations and could trigger broader investigations into trading practices. This event underscores the importance of robust internal controls and compliance programs for companies listed on both NASDAQ and the Canadian Securities Exchange.

What we're watching

Litigation Outcome
The resolution of the class action lawsuit will significantly impact Quantum BioPharma's financial standing and reputation, potentially triggering further scrutiny of its past dealings.
Bank Response
How CIBC and RBC respond to the allegations, including potential settlements or defenses, will set a precedent for similar cases involving market manipulation.
Investor Confidence
Whether Quantum BioPharma can restore investor confidence following these allegations will depend on transparency and proactive measures to ensure market integrity.
CID: 168